LEXXW تصريحات هيئة الأوراق المالية والبورصات - Lexaria Bioscience Corp. - Equity Warrant- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

CIK

1348362

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lexaria Bioscience Corp. - Equity Warrant

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

July 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-39874 LEXARIA BI
July 14, 2025	EX-10.2	Change Order to Project Agreement effective May 14, 2025 with Novotech (Australia) Pty Limited EXHIBIT 10.2 Change Order No. 1 Date: as per the last signature date of the Parties Parties 1. Novotech (Australia) Pty Limited ACN 071 874 881 of Level 19, 66 Goulburn Street, Sydney NSW 2000, Australia (Novotech) 2. Lexaria (AU) Pty Ltd of C/- Suite 1, Level 3, 62 Lygon Street, Carlton, Victoria, 3053, Australia (Sponsor) Background A On December 2, 2024, Novotech and Sponsor entered into a Proj
June 12, 2025	8-K	8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission File
April 28, 2025	EX-4.1	Form of Pre-Funded Warrant EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o
April 28, 2025	EX-1.2	Amendment to Engagement Agreement by and between the Company and H.C. Wainwright & Co., LLC, dated April 10, 2025 EXHIBIT 1.2 Execution Version April 10, 2025 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Richard Christopher, Chief Executive Officer Dear Mr. Christopher: Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of February 24, 2025, by and between Lexaria Bioscience Corp. (the “Company”) and H.C. Wai
April 28, 2025	EX-1.1	Engagement Agreement by and between the Company and H.C. Wainwright & Co., LLC, dated February 24, 2025 EXHIBIT 1.1 Execution Version February 24, 2025 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Richard Christopher, Chief Executive Officer Dear Mr. Christopher: This letter agreement (this “Agreement”), effective as of as of the date hereof, constitutes the agreement between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co.
April 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 24, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi
April 28, 2025	EX-99.2	Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock EXHIBIT 99.2 Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock Kelowna, British Columbia – April 28, 2025 – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering with a single institutional investor for the p
April 28, 2025	EX-99.1	Lexaria Announces $2 Million Registered Direct Offering of Common Stock EXHIBIT 99.1 Lexaria Announces $2 Million Registered Direct Offering of Common Stock Kelowna, British Columbia – April 25, 2025 – Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 2,000,000
April 28, 2025	424B5	Lexaria Bioscience Corp. 1,925,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 75,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284407 PROSPECTUS SUPPLEMENT (To Prospectus dated January 30, 2025) Lexaria Bioscience Corp. 1,925,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 75,000 Shares of Common Stock We are offering 1,925,000 shares of our common stock, par value $0.001 per share, and pre-funded warrants to purchase up to 75,000 shares of our common
April 28, 2025	EX-10.1	Form of Securities Purchase Agreement EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 24, 2025, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
April 28, 2025	EX-4.2	Form of Placement Agent Warrant EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-39874 LEXAR
April 14, 2025	EX-10.3	Form of Director Services Agreement EXHIBIT 10.3 Board of Directors Services Agreement (the “Agreement”) Effective this xx day of xx, 20xx. BETWEEN: LEXARIA BIOSCIENCE CORP. 100 – 740 McCurdy Road Kelowna, BC V1X 2P7 (the “Company”) AND: [name] [address] [city & state/province] [postal or zip code] (the “Director”) WHEREAS, the Company desires to retain the services of Director for the benefit of the Company and its stockholders; AN
February 5, 2025	EX-10.1	Amendment to the Capital on Demand™ Sales Agreement, dated as of February 5, 2025, by and between Lexaria Bioscience Corp. and JonesTrading Institutional Services LLC EXHIBIT 10.1 February 5, 2025 Lexaria Bioscience Corp. 100 - 740 McCurdy Road, Kelowna, BC, Canada V1X 2P7 Re: Amendment No. 1 to Capital on Demand™ Sales Agreement Ladies and Gentlemen: Reference is made to the Capital on Demand™ Sales Agreement, dated as of August 21, 2024 (the “Sales Agreement”), between Lexaria Bioscience Corp (the “Company”) and JonesTrading Institutional Services LLC (“Jones
February 5, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission
February 5, 2025	424B5	Up to $5,000,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-284407 PROSPECTUS SUPPLEMENT (To Prospectus dated January 30, 2025) Up to $5,000,000 of Common Stock We previously entered into a Capital on DemandTM Sales Agreement, dated August 21, 2024, as amended on February 5, 2025 (collectively, the “Sales Agreement”), with JonesTrading Institutional Services LLC, or Jones, relating to shares of our comm
January 28, 2025	CORRESP	VIA EDGAR AND FACSIMILE January 28, 2025 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance 100 F.
January 22, 2025	S-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on January 22, 2025 Registration Statement No.
January 22, 2025	EX-FILING FEES	Filing Fee Table (filed herewith) EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lexaria Bioscience Corp.
January 15, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 14, 2025 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission
January 10, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-39874 LEXAR
January 10, 2025	EX-10.4	Project Agreement effective December 2, 2024 with Novotech (Australia) Pty Limited EXHIBIT 10.4 Project Agreement No. 01 Date: as per last signature date Parties 1. Novotech (Australia) Pty Limited ACN 071 874 881 of Level 19, 66 Goulburn Street, Sydney NSW 2000, Australia (Novotech) 2. Lexaria (AU) Pty Ltd ACN 679 491 920 C/- Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053, Australia (Sponsor) Background A On August 28, 2024, Novotech and Sponsor entered into a Master
January 10, 2025	EX-10.5	Executive Employment Agreement dated December 31, 2024 with John Docherty EXHIBIT 10.5 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 31st day of December, 2024. BETWEEN: Kelowna Management Services Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“KMSC”) AND: John Docherty, residing at: [xx]1 (the “Executive”) WHEREAS KMSC serves as the Canadian corporation which operates and manages the rea
January 6, 2025	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lexaria Bioscience Corp.
January 6, 2025	S-8	As filed with the Securities and Exchange Commission on January 6, 2025 As filed with the Securities and Exchange Commission on January 6, 2025 Registration No.
January 3, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission
December 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2024 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 000-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission
December 16, 2024	POS AM	As filed with the Securities and Exchange Commission on December 16, 2024 As filed with the Securities and Exchange Commission on December 16, 2024 Registration No.
December 5, 2024	424B3	PROSPECTUS 4,551,019 Shares of Common Stock underlying certain Common Warrants Filed pursuant to Rule 424(b)(3) Registration No.333-283484 PROSPECTUS 4,551,019 Shares of Common Stock underlying certain Common Warrants This prospectus relates to the resale from time to time by the selling stockholder identified herein of up to 4,551,019 shares of common stock, $0.001 par value (“Common Stock”), underlying those certain private placement warrants (the “Common Warrants”). We re
December 3, 2024	CORRESP	VIA EDGAR AND FACSIMILE December 3, 2024 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F.
November 27, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
November 26, 2024	EX-19.1	Insider Trading and Black-Out Period Policy, effective June 14, 2019 EXHIBIT 19.1 INSIDER TRADING AND BLACKOUT PERIOD POLICY Effective June 14, 2019 Updated March 15, 2024 LEXARIA BIOSCIENCE CORP. INSIDER TRADING AND BLACKOUT PERIOD POLICY 1.0 PURPOSE Lexaria Bioscience Corp. (the "Company") is a publicly traded company, domiciled in British Columbia and listed on United States exchanges/marketplaces. As such, trades in the Company's securities1 are subject to both
November 26, 2024	EX-97.1	Clawback Policy, effective December 1, 2023 EXHIBIT 97.1 LEXARIA BIOSCIENCE CORP. CLAWBACK POLICY I. Purpose Lexaria Bioscience Corp. (the “Company”) is establishing this clawback policy (the “Policy”) in compliance with the Securities and Exchange Commission (“SEC”) and US stock exchange’s clawback rules and to align the interests of our current Executive Officers and those persons who were Executive Officers during any Look Back Period, w
November 26, 2024	EX-21.1	List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to Form 10-K filed November 26, 2024 ) EXHIBIT 21.1 Subsidiaries 100% owned by Lexaria Bioscience Corp. Poviva Corp. Lexaria Nutraceutical Corp. Lexaria Hemp Corp. Lexaria Pharmaceutical Corp. Lexaria (AU) Pty Ltd Kelowna Management Services Corp. Lexaria CanPharm Holding Corp. 100% owned by Lexaria CanPharm Holding Corp. Lexaria CanPharm ULC 83.333% owned by Lexaria Bioscience Corp. Lexaria Nicotine LLC
November 26, 2024	S-3	As filed with the Securities and Exchange Commission on November 26, 2024. As filed with the Securities and Exchange Commission on November 26, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in Its Charter) Nevada 20-2000871 (State or Other Jurisdiction of Incorporation or Organization) (I.R.
November 26, 2024	EX-10.9	Executive Employment Agreement dated August 31, 2024 with Richard Christopher EXHIBIT 10.9 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 31st day of August, 2024. BETWEEN: Lexaria Bioscience Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“LBC”) AND: Richard Christopher of [xx]1 (the “Executive”) WHEREAS LBC serves as the Nasdaq listed parent company of the following subsidiaries: Kelowna Manag
November 26, 2024	EX-FILING FEES	Filing Fee Table (filed herewith). EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) Lexaria Bioscience Corp.
November 26, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-39874 Lexaria Bio
November 26, 2024	EX-10.10	Executive Employment Agreement dated October 1, 2024 with Michael Shankman (incorporated by reference to Exhibit 10.10 to our Annual Report on Form 10-K filed November 26, 2024) EXHIBIT 10.10 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 1st day of October, 2024. BETWEEN: Lexaria Bioscience Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“LBC”) AND: Michael Shankman, having an address at: [xx]1 (the “Executive”) WHEREAS LBC serves as the Nasdaq listed parent company of the following subsidiar
November 14, 2024	SC 13G/A	LEXX / Lexaria Bioscience Corp. / Invenomic Capital Management LP - AMENTMENT NO. 3 Passive Investment SC 13G/A 1 o10302414sc13ga3.htm AMENTMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.3 )* LEXARIA BIOSCIENCE CORP. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 52886N406 (CUSIP Number) 2/22/2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to
November 12, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
October 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 16, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 16, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
October 16, 2024	EX-10.1	Form of Securities Purchase Agreement with certain purchasers dated October 14, 2024 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed October 16, 2024) EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 14, 2024, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition
October 16, 2024	EX-99.2	Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EXHIBIT 99.2 Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Kelowna, British Columbia – October 16, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market u
October 16, 2024	EX-4.2	Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed October 16, 2024) EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 14, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 14, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
October 16, 2024	EX-1.1	Engagement Agreement by and between the Company and H.C. Wainwright & Co., LLC, dated September 4, 2024 (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed October 16, 2024) EXHIBIT 1.1 Execution Version September 4, 2024 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. 100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Chris Bunka, Chief Executive Officer Dear Mr. Bunka: This letter agreement (this “Agreement”), effective as of as of the date hereof, constitutes the agreement between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwri
October 16, 2024	424B5	Lexaria Bioscience Corp. 1,633,987 Shares of Common Stock Prospectus Supplement To Prospectus dated February 4, 2022 Filed pursuant to Rule 424(b)(5) Registration No.
October 16, 2024	EX-4.1	Form of Private Placement Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed October 16, 2024) EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 16, 2024	EX-99.1	1 EXHIBIT 99.1 KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share in a registered direct offering priced at-the-
October 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 1, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 1, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F
September 5, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 31, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F
September 5, 2024	EX-99.1	Lexaria Releases Strategic Letter from the Outgoing CEO EXHIBIT 99.1 Lexaria Releases Strategic Letter from the Outgoing CEO Kelowna, British Columbia – September 5, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer (“CEO”) Chris Bunka as a strategic update to all stakeholders. CEO LETTER TO STAKEHOLDER
August 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 21, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 21, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
August 22, 2024	EX-1.1	Capital on Demand™ Sales Agreement, dated as of August 21, 2024 by and between Lexaria Bioscience Corp. and JonesTrading Institutional Services LLC (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed on August 22, 2024) EXHIBIT 1.1 Lexaria Bioscience Corp Common Stock ($0.001 par value per share) Capital on Demand™ Sales Agreement August 21, 2024 JonesTrading Institutional Services LLC 325 Hudson Street., 6th Floor New York, NY 10013 Ladies and Gentlemen: Lexaria Bioscience Corp, a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agen
August 21, 2024	424B5	Up to $20,000,000 of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-262402 PROSPECTUS SUPPLEMENT (To Prospectus dated February 4, 2022) Up to $20,000,000 of Common Stock We have entered into a Capital on DemandTM Sales Agreement, or Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading, dated August 21, 2024, relating to shares of our common stock, par value $0.001 per share, or common
July 17, 2024	EX-99.1	Positive Interim Body Weight Results from Lexaria’s Diabetes Animal Study EXHIBIT 99.1 Positive Interim Body Weight Results from Lexaria’s Diabetes Animal Study · DehydraTECH appears to work with a second GLP-1 drug – liraglutide · DehydraTECH appears to be working with semaglutide both with and without SNAC technology · DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 · Dosing in the final four study arms has now begun Kelowna, British Columbia
July 17, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
July 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXARIA BI
July 12, 2024	EX-4.2	Form of Tail Warrant issued on April 30, 2024 EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
June 11, 2024	424B3	Lexaria Bioscience Corp. 2,917,032 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-279909 PROSPECTUS Lexaria Bioscience Corp. 2,917,032 Shares of Common Stock This prospectus relates to the resale from time to time by the selling stockholder named in this prospectus (the “Selling Stockholder”) of up to 2,917,032 shares of our common stock, par value $0.001 per share, issuable upon the exercise of an outstanding warrant issued
June 7, 2024	CORRESP	VIA EDGAR AND FACSIMILE June 7, 2024 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F.
June 3, 2024	S-1	As filed with the U.S. Securities and Exchange Commission on June 3, 2024 As filed with the U.S. Securities and Exchange Commission on June 3, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact Name of Registrant as Specified in its Charter) Nevada 2000 20-2000871 (State or other jurisdiction of incorporation or organization) (Primary Standard Indust
June 3, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables S-1 (Form Type) Lexaria Bioscience Corp.
April 30, 2024	EX-4.1	Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed April 30, 2024) EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi
April 30, 2024	EX-10.1	Warrant Exercise Agreement between the Company and Armistice Capital Master Fund Ltd. (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on April 30, 2024) EXHIBIT 10.1 LEXARIA BIOSCIENCE CORP. April 30, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Lexaria Bioscience Corp. (the “Company”) is pleased to offer to you the opportunity to exercise the warrants to purchase shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), set forth on Exhibit
April 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi
April 9, 2024	EX-10.5	Executive Employment Agreement dated December 31, 2024 with John Docherty (incorporated by reference to Exhibit 10.5 to our Quarterly Report on Form 10-Q filed January 10, 2025) EXHIBIT 10.5 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 14th day of March, 2024. BETWEEN: Lexaria Bioscience Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“LBC”) AND: Nelson Cabatuan of [**]1 (the “Executive”) WHEREAS LBC serves as the Nasdaq listed parent company of the following subsidiaries: Kelowna Management
April 9, 2024	EX-10.6	Amended and Restated Definitive Intellectual Property License Agreement between Lexaria Hemp Corp. and Premier Anti-aging Co., Ltd., dated March 15, 2024 (incorporated by reference to Exhibit 10.6 to our Quarterly Report on Form 10-Q filed on April 9, 2024) EXHIBIT 10.6 Amended and Restated INTELLECTUAL PROPERTY LICENSE AGREEMENT This Amended and Restated Intellectual Property License Agreement is made and entered as of the 15th day of March, 2024 (the “Effective Date”) by and between Lexaria Hemp Corp., a US corporation with offices at #100 – 740 McCurdy Road, Kelowna, British Columbia, Canada V1X 2P7, Canada (the “LICENSOR”), and Premier Anti-Aging
April 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXAR
March 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi
March 20, 2024	424B3	PROSPECTUS Lexaria Bioscience Corp. 1,612,989 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-277863 PROSPECTUS Lexaria Bioscience Corp. 1,612,989 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 1,612,989 shares of our common stock, par value $0.001 per share, issuable upon the exercise of outstanding warrants issued on February 16, 2024 pursuan
March 18, 2024	CORRESP	VIA EDGAR AND FACSIMILE March 18, 2024 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F.
March 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 14, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi
March 12, 2024	S-1	As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No.
March 12, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT107 Calculation of Filing Fee Tables S-1 (Form Type) Lexaria Bioscience Corp.
March 6, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 1, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 29, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 29, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
February 16, 2024	EX-1.2	Engagement Agreement Amendment by and between the Company and H.C. Wainwright & Co., LLC, dated February 12, 2024 (incorporated by reference to Exhibit 1.2 to our Current Report on Form 8-K filed February 16, 2024) EXHIBIT 1.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” Execution Version February 15, 2024 STRICTLY CONFIDENTIAL Reference is hereby made to that certain engagement letter, dated as of February 12, 2024 (the “Engagemen
February 16, 2024	EX-99.1	Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EXHIBIT 99.1 Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Kelowna, British Columbia – February 15, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into definitive agreements for the purchase and sale of 1,558,443 shares of commo
February 16, 2024	EX-99.2	Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules EXHIBIT 99.2 Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Kelowna, British Columbia – February 16, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-marke
February 16, 2024	EX-1.1	Engagement Agreement by and between the Company and H.C. Wainwright & Co., LLC, dated February 12, 2024 (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed February 16, 2024) EXHIBIT 1.1 Execution Version February 12, 2024 STRICTLY CONFIDENTIAL Lexaria Bioscience Corp. 100 – 740 McCurdy Road Kelowna, BC V1X 2P7 Canada Attn: Chris Bunka, Chief Executive Officer Dear Mr. Bunka: This letter agreement (this “Agreement”), effective as of February 12, 2023, constitutes the agreement between Lexaria Bioscience Corp. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”
February 16, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
February 16, 2024	EX-4.2	Form of Private Placement Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed February 16, 2024) EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
February 16, 2024	EX-4.1	Form of Pre-Funded Warrant EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: February 16, 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
February 16, 2024	EX-10.1	Form of Securities Purchase Agreement with certain purchasers dated February 14, 2024 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed February 16, 2024) EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 14, 2024, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio
February 16, 2024	EX-4.3	Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K filed February 16, 2024) EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
February 16, 2024	424B5	Lexaria Bioscience Corp. 1,444,741 Shares of Common Stock Pre-Funded Warrants to Purchase 113,702 Shares of Common Stock Prospectus Supplement Filed pursuant to Rule 424(b)(5) To Prospectus dated February 4, 2022 Registration No.
February 14, 2024	SC 13G/A	LEXX / Lexaria Bioscience Corp. / Invenomic Capital Management LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 lexx130240sc13ga2.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* LEXARIA BIOSCIENCE CORP. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 52886N406 (CUSIP Number) 12/31/2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box
January 30, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2024 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
January 24, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2024 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
January 24, 2024	POS AM	As filed with the Securities and Exchange Commission on January 24, 2024 As filed with the Securities and Exchange Commission on January 24, 2024 Registration No.
January 24, 2024	EX-99.1	CEO LETTER TO STAKEHOLDERS EXHIBIT 99.1 CEO LETTER TO STAKEHOLDERS According to the Wall Street Journal, near the end of 2023, there were 446 companies listed on the Nasdaq that were trading under $1 and risking being de-listed; compared to nearly nil in 2021. It was a tough year for microcap companies, which are often too early-stage to have profitable operations and withstand the harsh realities of the investment banking
January 18, 2024	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lexaria Bioscience Corp.
January 18, 2024	S-8	As filed with the Securities and Exchange Commission on January 18, 2024 As filed with the Securities and Exchange Commission on January 18, 2024 Registration No.
January 18, 2024	EX-4.1	Form of Equity Incentive Plan (incorporated by reference to Exhibit 4.1 to our Form S-8 Registration Statement filed on January 18, 2024) EXHIBIT 4.1 LEXARIA BIOSCIENCE CORP. EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentive to Employees, Directors, and Consultants, and (c) to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Opt
January 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 Lexar
January 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 4, 2024 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F
January 4, 2024	EX-99.1	Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide EXHIBIT 99.1 Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide Final results from a human pilot study show DehydraTECHTM-powered semaglutide outperforms Rybelsus®: · Sustained higher levels of semaglutide in blood; · Better blood glucose control; · Faster achievement of peak drug delivery; and · Reduced side effects. Kelowna, British Columb
December 8, 2023	424B3	Lexaria Bioscience Corp. 1,618,330 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-275810 PROSPECTUS Lexaria Bioscience Corp. 1,618,330 Shares of Common Stock This prospectus relates to the resale by the selling stockholder named in this prospectus from time to time of up to 1,618,330 shares of our common stock, par value $0.001 per share, issuable upon the exercise of outstanding warrants issued in October 2023 (the “Warrant
December 6, 2023	CORRESP	VIA EDGAR AND FACSIMILE December 6, 2023 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F.
November 30, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Lexaria Bioscience Corp.
November 30, 2023	S-1	As filed with the Securities and Exchange Commission on November 30, 2023 As filed with the Securities and Exchange Commission on November 30, 2023 Registration No.
November 20, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-52138 Lexaria Bioscienc
November 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 3, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
October 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 17, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
October 16, 2023	EX-99	Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn EXHIBIT 99.1 Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn · Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded · Minimum ongoing payments, royalties and manufacturing revenues part of the agreement Kelowna, British Columbia – October 13, 2023 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the
October 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F
October 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 10, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 10, 2023 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
October 12, 2023	EX-99.1	Lexaria Granted Two New Patents in Canada · Lexaria now holds 37 granted patents world-wide · Potential application in treating nicotine addiction EXHIBIT 99.1 Lexaria Granted Two New Patents in Canada · Lexaria now holds 37 granted patents world-wide · Potential application in treating nicotine addiction Kelowna, British Columbia – October 12, 2023 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has been granted two new patents by the Canadian
October 3, 2023	EX-1.1	Placement Agency Agreement with Maxim Group LLC dated September 28, 2023 (incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed October 3, 2023) EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT September 28, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Lexaria Bioscience Corp., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $1,569,780.10 of registered and unregistered securities of the Company, including, but
October 3, 2023	EX-4.1	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed October 3, 2023) EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he
October 3, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 28, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commissio
October 3, 2023	EX-10.1	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed October 3, 2023) EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2023, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi
October 3, 2023	EX-4.2	Form of Private Placement Warrant (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed October 3, 2023) EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 2, 2023	424B5	Lexaria Bioscience Corp. 889,272 Shares of Common Stock Pre-Funded Warrants to Purchase 729,058 Shares of Common Stock Prospectus Supplement Filed pursuant to Rule 424(b)(5) To Prospectus dated February 4, 2022 Registration No.
August 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F
August 23, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
August 9, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
July 28, 2023	EX-99.1	Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study EXHIBIT 99.1 Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study Kelowna, British Columbia – July 28, 2023 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”). The es
July 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 26, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 26, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
July 14, 2023	EX-10.3	Work Order for Start-Up Activities with InClin, Inc. (incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q filed July 14, 2023) EXHIBIT 10.3
July 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXARIA BI
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 22, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
June 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
May 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 9, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
May 10, 2023	EX-99.1	Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering EXHIBIT 99.1 Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering KELOWNA, BC / ACCESSWIRE / MAY 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the pricing of its public offering of 2,106,000 units, with each unit consisting of one share of common stock and one warrant to p
May 10, 2023	424B4	PROSPECTUS 2,106,000 Units, Each Unit Consisting of One Share of Common Stock and One Common Warrant to Purchase One Share of Common Stock Common Stock Underlying the Common Warrants Filed pursuant to Rule 424(b)(4) Registration No. 333-271096 PROSPECTUS 2,106,000 Units, Each Unit Consisting of One Share of Common Stock and One Common Warrant to Purchase One Share of Common Stock Common Stock Underlying the Common Warrants We are offering on a best-efforts basis 2,106,000 units, each unit consisting of one share of common stock and one common warrant to purchase one share of c
May 10, 2023	EX-10.2	Placement Agency Agreement with Maxim Group LLC dated May 8, 2023 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed May 10, 2023) EXHIBIT 10.2 PLACEMENT AGENCY AGREEMENT May 8, 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Lexaria Bioscience Corp., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,000,7000 of registered units (the “Units”) of the Company, each Unit consisting of either
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Lexaria Bioscience Corp. (Exact name of registrant as specified in its charter) Nevada 001-39874 20-2000871 (State or other jurisdiction of incorporation) (Commission File
May 5, 2023	CORRESP	VIA EDGAR May 5, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Lexaria Bioscience Corp. Registration Statement on Form S-1, as amended File No. 333-271096 Ladies and Gentlemen: As the placement agent of the proposed offering of Lexaria Bioscience Corp. (the “Company”), we hereby join the Company’s request for acceler
May 5, 2023	CORRESP	VIA EDGAR AND FACSIMILE May 5, 2023 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F.
May 4, 2023	CORRESP	Lexaria Bioscience Corp. Lexaria Bioscience Corp. 100-740 McCurdy Road, Kelowna British Columbia, Canada, V1X 2P7 May 4, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Lexaria Bioscience Corp Registration Statement on Form S-1, as amended Initially filed on April 3, 2023, as amende
May 4, 2023	CORRESP	VIA EDGAR May 4, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Lexaria Bioscience Corp.
May 3, 2023	CORRESP	VIA EDGAR May 3, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Lexaria Bioscience Corp. Registration Statement on Form S-1, as amended File No. 333-271096 Ladies and Gentlemen: As the placement agent of the proposed offering of Lexaria Bioscience Corp. (the “Company”), we hereby join the Company’s request for acceler
May 3, 2023	CORRESP	VIA EDGAR AND FACSIMILE May 3, 2023 VIA EDGAR AND FACSIMILE United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F.
April 28, 2023	EX-4.5	Form of Warrant (incorporated by reference to Exhibit 4.5 to our Registration Statement on Form S-1 filed April 28, 2023) EXHIBIT 4.5 COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: April , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initi
April 28, 2023	EX-10.8	Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.8 to our Registration Statement on Form S-1 filed April 28, 2023) EXHIBIT 10.8 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April , 2023, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se
April 28, 2023	EX-1.1	Form of Placement Agent Agreement* EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT April , 2023 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Lexaria Bioscience Corp., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $[] of registered units (the “Units”) of the Company, each Unit consisting of either (a) one
April 28, 2023	S-1/A	As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No.
April 28, 2023	EX-10.9	Form of Warrant Agency Agreement (incorporated by reference to Exhibit 10.9 to our Registration Statement on Form S-1 filed April 28, 2023) EXHIBIT 10.9 LEXARIA BIOSCIENCE CORP. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Warrant Agent Warrant Agency Agreement Dated as of April , 2023 EXECUTION VERSION WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of April , 2023 (“Agreement”), between Lexaria Bioscience Corp., a corporation organized under the laws of the State of Nevada (the “Company”), and Compute
April 28, 2023	EX-4.6	Form of Pre-funded Warrant* EXHIBIT 4.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: April , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d
April 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 000-52138 LEXAR
April 3, 2023	EX-FILING FEES	Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lexaria Bioscience Corp.
April 3, 2023	S-1	As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No.
March 22, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 lxrpdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-
March 10, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
March 3, 2023	EX-99.1	Lexaria’s DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels EXHIBIT 99.1 Lexaria’s DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels Kelowna, British Columbia – March 2, 2023 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that its diabetes animal model study DIAB-A22-1 has completed and produced at least three
March 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 2, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
February 10, 2023	SC 13G/A	LEXX / Lexaria Bioscience Corp / Invenomic Capital Management LP - FORM 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1) Lexaria Bioscience Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 52886N406 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
January 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
January 18, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file numb
January 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 13, 2023 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
January 17, 2023	EX-99.1	CEO LETTER TO STAKEHOLDERS EXHIBIT 99.1 CEO LETTER TO STAKEHOLDERS As 2022 came to a close, it isn’t news that nearly all companies – not to mention most people - are facing challenges not experienced in years. Lexaria continues to navigate well and is focused on those things it can control such as applied R&D designed to entice others to work with us commercially. Inflation rates running at 40-year highs have prompted inte
January 17, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIE
December 28, 2022	POS AM	As filed with the Securities and Exchange Commission on December 28, 2022 POS AM 1 lxrpposam.htm POS AM As filed with the Securities and Exchange Commission on December 28, 2022 Registration No. 333-238915 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevad
December 21, 2022	POS AM	As filed with the Securities and Exchange Commission on December 21, 2022 As filed with the Securities and Exchange Commission on December 21, 2022 Registration Nos.
December 6, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-52138
November 30, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
November 28, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 25, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
November 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-52138 LEXARIA BIOSCIENC
November 28, 2022	EX-16.1	Letter of Davidson & Company LLP dated November 28, 2022 EX-16.1 2 lxrpex161.htm LETTER OF DAVIDSON EXHIBIT 16.1 November 28, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549, USA Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated November 25, 2022 of Lexaria Bioscience Corp. (the “Company”) and are in agreement with the statements contained in paragraphs 2 and 3 on Page 2 therein. We have no basis to agree or
October 28, 2022	EX-99.1	Lexaria’s Human Clinical Hypertension Study a Success EXHIBIT 99.1 Lexaria’s Human Clinical Hypertension Study a Success HYPER-H21-4 using DehydraTECH-CBD evidenced: · Exceptional safety and tolerability · Statistically significant lowering of 24-hour ambulatory blood pressure (“BP”) · BP lowered for the entire 5-week study duration · BP lowered both for patients currently taking other antihypertensive drugs as well as patients not taking any other a
October 28, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
September 2, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 2, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
August 15, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F
August 12, 2022	424B5	Lexaria Bioscience Corp. Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-262402 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 4, 2022) Lexaria Bioscience Corp. $5,925,000 Common Stock We have entered into an equity distribution agreement (the ?Sales Agreement?) with Maxim Group LLC (?Maxim? or the ?Distribution Agent?), dated August 12, 2022, relating to the sale of shares of our common stock offered
August 12, 2022	8-K	Financial Statements and Exhibits, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F
August 12, 2022	EX-1.1	Equity Distribution Agreement with Maxim Group LLC (incorporated by reference as Exhibit 1.1 to our Current Report on Form 8-K filed August 12, 2022) EX-1.1 2 lxrpex11.htm EQUITY DISTRIBUTION AGREEMENT EXHIBIT 1.1 Lexaria Bioscience Corp. Up to $5,925,000 of Shares of Common Stock Equity Distribution Agreement August 12, 2022 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: Lexaria Bioscience Corp., a Nevada corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), a
July 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIENCE C
July 14, 2022	EX-10.3	Intellectual Property License Agreement dated May 20, 2022 between Lexaria Hemp Corp. and Premier Wellness Science Co., Ltd. (incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q filed July 14, 2022) EXHIBIT 10.3 CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN EXCLUDED WHERE ITS DISCLOSURE WOULD BE COMPETITIVELY HARMFUL. INTELLECTUAL PROPERTY LICENSE AGREEMENT This Intellectual Property License Agreement (this ?Agreement?) dated as of May 20, 2022 (the ?Effective Date?) is made by and between Lexaria Hemp Corp., a US corporation with offices at #100 ? 740 McCurdy Road, Kelowna, British Columbia,
June 22, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi
June 9, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
June 3, 2022	8-K	Other Events, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
June 1, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 31, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
April 20, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi
April 20, 2022	EX-99.1	Zacks Investment Research Report Update EXHIBIT 99.1
April 13, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 13, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 13, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIE
February 14, 2022	SC 13G	LEXX / Lexaria Bioscience Corp / Invenomic Capital Management LP - LEXARIA - 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.) Lexaria Bioscience Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 52886N406 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 14, 2022	SC 13G/A	LEXX / Lexaria Bioscience Corp / L1 Capital Global Opportunities Master Fund, Ltd. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 1 Under the Securities Exchange Act of 1934 LEXARIA BIOSCIENCE CORP. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 52886N406 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 2, 2022	EX-99.1	Zacks Investment Research Report Update EXHIBIT 99.1
February 2, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
February 1, 2022	CORRESP	Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, British Columbia V1X 2P7 CORRESP 1 filename1.htm Lexaria Bioscience Corp. #100 – 740 McCurdy Road Kelowna, British Columbia V1X 2P7 1-250-765-6424 February 1, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Mr. Gary Guttenberg Re: Lexaria Bioscience Corp. Registration Statement on Form S-3 Filed January 28, 2022 File No. 333-262402 Ladies and Gent
January 28, 2022	S-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on January 28, 2022 Registration Statement No.
January 27, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2022 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
January 27, 2022	EX-99.1	Lexaria Provides Annual Letter From the CEO EXHIBIT 99.1 Lexaria Provides Annual Letter From the CEO Kelowna, British Columbia ? January 27, 2022 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms, is pleased to provide an annual letter from CEO, Chris Bunka and a thorough strategic update to all stakeholders. Dear Shareholders, Will anyone ever forget 2021?
January 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIE
January 14, 2022	EX-10.2	Management Services Agreement dated Dec. 31, 2021 with C.A.B. Financial Services Ltd. (Chris Bunka) (filed on Form 10-Q January 14, 2022 Exh 10.2) EXHIBIT 10.2 INDEPENDENT CONTRACTOR AGREEMENT THIS CONTRACT IS MADE AS OF DECEMBER 31, 2021 BETWEEN: LEXARIA BIOSCIENCE CORP. of 100 ? 740 McCurdy Road, Kelowna, BC V1X 2P7 (hereinafter referred to as the ?Company?) OF THE FIRST PART - and - C.A.B. FINANCIAL SERVICES LTD. of [xx]1 (hereinafter referred to as the ?Contractor?) OF THE SECOND PART WHEREAS Company wishes to contract for the services o
January 14, 2022	EX-10.1	Executive Employment Agreement dated Dec. 31, 2021 with John Docherty (filed on Form 10-Q January 14, 2022 Exh 10.1) EX-10.1 2 lxrpex101.htm EX-10.1 EXHIBIT 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of the 31st day of December, 2021. BETWEEN: Kelowna Management Services Corp. having an address at: 100 – 740 McCurdy Road, Kelowna, BC V1X 2P7 (“KMSC”) AND: John Docherty, residing at: [xx]i1 (the “Executive”) WHEREAS KMSC serves as the Canadian corporation w
January 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
December 28, 2021	424B3	1,659,448 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants 424B3 1 lxrp424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-250326 and 333-252031 PROSPECTUS 1,659,448 Shares of Common Stock Issuable Upon Exercise of Outstanding Warrants This prospectus relates to the issuance of up to 1,659,448 shares of our common stock, par value $0.001 per share, upon the exercise of the following warrants: (1) warrants to purchase 1,575,951 shares of
December 28, 2021	424B3	PROSPECTUS 434,085 SHARES OF COMMON STOCK 424B3 1 lxrp424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-238915 PROSPECTUS 434,085 SHARES OF COMMON STOCK This prospectus relates to the offering and resale by the selling stockholders identified herein of up to 434,085 shares of common stock issued or issuable to such selling stockholders, including 352,763 shares of common stock issuable upon the exercise of outstanding
December 20, 2021	EX-99.1	Zacks Investment Research Report Update EXHIBIT 99.1
December 20, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 16, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
December 17, 2021	POS AM	As filed with the Securities and Exchange Commission on December 17, 2021 As filed with the Securities and Exchange Commission on December 17, 2021 Registration No.
December 17, 2021	POS AM	As filed with the Securities and Exchange Commission on December 17 2021 As filed with the Securities and Exchange Commission on December 17 2021 Registration Number 333-250326 and 333-252031 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Post- Effective Amendment No.
December 16, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
December 16, 2021	EX-10.1	Media Buys Agreement with SRAX (incorporated by reference as Exhibit 10.1 to our Current Report on Form 8-K filed December 16, 2021) EXHIBIT 10.1 TERMS AND CONDITIONS FOR PAYMENT OF MEDIA BUYS VIA SECURITIES These Standard Terms and Conditions for Payment of Media Buys Via Securities (?Securities Terms?) are intended to supplement Terms and Conditions (as defined below). 1. Definitions. Any terms not defined herein will have the meaning ascribed to them in the Standard Terms and Conditions for Internet Advertising for Media Buy
November 29, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [] to [] Commission file number 000-52138 LEXARIA BIOSCIENC
November 29, 2021	EX-21.1	List of Subsidiaries of the Registrant (Filed on Form 10-K November 29, 2021 Exh 21.1) EXHIBIT 21.1 Subsidiaries of the Registrant Lexaria CanPharm ULC, a British Columbia Canada unlimited liability corporation PoViva Corp., a Nevada corporation Lexaria Hemp Corp., a Delaware corporation Lexaria Nicotine LLC, a Delaware limited liability corporation Lexaria CanPharm Holding Corp., a Nevada corporation Lexaria Pharmaceutical Corp., a Delaware corporation Kelowna Management Services C
November 10, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
September 23, 2021	EX-99.1	Zacks Investment Research Report EXHIBIT 99.1
September 23, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 20, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commissio
September 8, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 7, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission
September 8, 2021	EX-99.1	Lexaria’s Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD rela EXHIBIT 99.1 Lexaria?s Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo Kelowna, British Columbia ? September 7, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the ?Company? or
September 8, 2021	EX-99.2	Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension Positive results using DehydraTECH-CBD support progressing to FDA IND application EXHIBIT 99.2 Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension Positive results using DehydraTECH-CBD support progressing to FDA IND application Kelowna, British Columbia ? September 8, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms today announced it is for
August 24, 2021	EX-99.1	Fundamental Research Corp. Report EXHIBIT 99.1
August 24, 2021	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 23, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 23, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission F
July 30, 2021	EX-99.1	Lexaria’s DehydraTECH-CBD Lowers Blood Pressure Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability EXHIBIT 99.1 Lexaria?s DehydraTECH-CBD Lowers Blood Pressure Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability Kelowna, British Columbia ? July 29, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms is extremely pleased to iss
July 30, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 27, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
July 30, 2021	S-8	As filed with the Securities and Exchange Commission on July 30, 2021 As filed with the Securities and Exchange Commission on July 30, 2021 Registration No.
July 27, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
July 15, 2021	EX-10.1	Employment Agreement dated April 15, 2021 with Gregory Downey (incorporated by reference to Exhibit 10.1 to our Current Report on Form 10-Q filed July 15, 2021) EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS AGREEMENT made the 15th day of April, 2021. BETWEEN: Kelowna Management Services Corp. 100 ? 740 McCurdyRoad Kelowna, BC V1X 2P7 (the ?Employer?) AND: Gregory J. Downey [**]1 (the ?Employee?) WHEREAS: A. The Employer is in the business of providing management services to its affiliates (the ?Affiliates?) as that term is defined in National Instrument 45-106 ?
July 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIENCE C
July 15, 2021	EX-4.1	Equity Incentive Plan (Filed on Form S-8 July 30, 2021) EXHIBIT 4.1 LEXARIA BIOSCIENCE CORP. EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentive to Employees, Directors, and Consultants, and (c) to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock Opt
July 6, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
June 30, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
June 16, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 15, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fil
June 16, 2021	EX-99.1	Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 EXHIBIT 99.1 Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs DehydraTECH? improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 Kelowna, British Columbia - June 15, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the ?Company? or ?Lexaria?), a global innovator in drug de
June 9, 2021	EX-99.3	Lexaria Announces Issuance of Options EXHIBIT 99.3 Lexaria Announces Issuance of Options Kelowna, British Columbia? June 8, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms announces the issuance of 87,935 stock options. Stock Option Issuance Lexaria announces that on June 8, 2021 it has issued an aggregate 87,935 stock options to a to
June 9, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
June 9, 2021	EX-99.2	Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1 EXHIBIT 99.2 Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1 ? Dosing is complete in first of three human clinical studies hoped to validate Lexaria?s patented technology for hypertension relief ? Study tested an advanced ?DehydraTECH? 2.0? CBD formulation ? Second human clinical study, HYPER-H21-2, to commence immediately Kelowna, British Columbia, June 7, 2021 ?
June 9, 2021	EX-99.1	Lexaria’s DehydraTECHTM-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus EXHIBIT 99.1 Lexaria?s DehydraTECHTM-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus Kelowna, British Columbia, June 3, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting
June 9, 2021	EX-99.4	Lexaria Provides Progress Report on Six R&D Programs EXHIBIT 99.4 Lexaria Provides Progress Report on Six R&D Programs ? All studies are using DehydraTECH? 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine ? These studies are part of Lexaria?s 2021 applied R&D program intended to enable opportunities for strategic partnerships Kelowna, British Columbia, June 9, 2021 ? Lexaria Bioscience C
May 14, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
May 12, 2021	EX-99.1	Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 EXHIBIT 99.1 Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 ? Up to 2,178% more CBD delivered into bloodstream* ? Up to 1,737% more CBD delivered into brain tissue* Kelowna, British Columbia, May 6, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms, is pleased to announce succe
May 12, 2021	EX-99.3	Lexaria Strengthens its International Patent Portfolio to 19 Patents Granted New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia EXHIBIT 99.3 Lexaria Strengthens its International Patent Portfolio to 19 Patents Granted New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia Kelowna, British Columbia, May 12, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms
May 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission File
May 12, 2021	EX-99.2	Lexaria Announces Cancellation of Options EXHIBIT 99.2 Lexaria Announces Cancellation of Options Kelowna, British Columbia? May 7, 2021 ? Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the ?Company? or ?Lexaria?), a global innovator in drug delivery platforms announces the cancellation of 87,935 stock options. Stock Option Cancellation Lexaria announces that on May 7, 2021 it has cancelled, with the approval and autho
April 16, 2021	EX-99.1	Lexaria Appoints New Chief Financial Officer And Issues Consultant Warrants EXHIBIT 99.1 Lexaria Appoints New Chief Financial Officer And Issues Consultant Warrants Kelowna, British Columbia, April 15, 2021 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces the appointment of a new Chief Financial Officer and the issuance of share purchase warrants to third party consu
April 16, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 15, 2021 LEXARIA BIOSCIENCE CORP. (Exact name of registrant as specified in its charter) Nevada 000-52138 20-2000871 (State or other jurisdiction of incorporation) (Commission Fi
April 14, 2021	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number LEXARIA BIOSCIENCE CORP.
March 3, 2021	424B3	483,568 SHARES OF COMMON STOCK Filed pursuant to Rule 424(b)(3) Registration No. 333-238915 PROSPECTUS 483,568 SHARES OF COMMON STOCK This prospectus relates to the offering and resale by the selling stockholders identified herein of up to 483,568 shares of common stock issued or issuable to such selling stockholders, including 353,512 shares of common stock issuable upon the exercise of outstanding warrants. The selling stockh
February 26, 2021	POS AM	- POS AM As filed with the Securities and Exchange Commission on February 26, 2021 Registration No.
February 24, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9) LEXARIA BIOSCIENCE CORP. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 52886N406 (CUSIP Number) Christopher Bunka c/o Lexaria Bioscience Corp. 100 – 740 McCurdy Road, Kelowna BC V1X 2P7 250-765-6424 (Name, Addr
February 12, 2021	POS AM	- POS AM As filed with the Securities and Exchange Commission on February 12, 2021 Registration No.
January 20, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SC13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 LEXARIA BIOSCIENCE CORP. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 52886N406 (CUSIP Number) January 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
January 14, 2021	424B4	1,828,571 Shares of Common Stock Warrants to purchase up to 1,828,571 Shares of Common Stock PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration Nos. 333-250326 and 333-252031 1,828,571 Shares of Common Stock Warrants to purchase up to 1,828,571 Shares of Common Stock We are offering for sale 1,828,571 shares of our common stock, par value $0.001 per share. Each share of our common stock is being sold with one warrant to purchase one share of our common stock, at a combined public of
January 14, 2021	EX-4.3	Warrant Agency Agreement, dated January 11, 2021 (incorporated by reference as exhibit 4.3 to our Current Report on Form 8-K filed January 14, 2021) EXHIBIT 4.3 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of January 11, 2021 (“Agreement”), among Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and Computershare, Inc., a Delaware corporation (“Computershare”), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (collectively with Computershare, the “Warrant Agent
January 14, 2021	EX-1.1	Underwriting Agreement with H.C. Wainwright & Co. LLC (incorporated by reference as Exhibit 1.1 to our Current Report on Form 8-K filed January 14, 2021) EXHIBIT 1.1 1,828,571 SHARES of Common Stock, 0 PREFUNDED WARRANTS, AND 1,828,571 COMMON Warrants OF LEXARIA BIOSCIENCE CORP. UNDERWRITING AGREEMENT January 12, 2021 H.C. Wainwright & Co., LLC As the Representative of the several underwriters, if any, named in Schedule I hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: The undersigned, Lexaria Bioscience Corp., a company incor
January 14, 2021	EX-3.1	Amended and Restated Articles of Incorporation (Filed on Form 8-K January 14, 2021 Exh. 3.1) EXHIBIT 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF LEXARIA BIOSCIENCE CORP. Pursuant to NRS Chapter 78 Lexaria Bioscience Corp. (the “Corporation”), a corporation incorporated under the laws of Nevada on December 9, 2004, hereby amends and restates its Articles of Incorporation to embody as one document its original Articles of Incorporation and all amendments thereto, pursuant to Secti
January 14, 2021	EX-99.1	Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering EXHIBIT 99.1 Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Tuesday, January 12, 2021 7:00 AM Topic: Exchange Listing Upgrade KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin trading on th
January 14, 2021	EX-4.1	Form of Warrant (incorporated by reference as Exhibit 4.1 to our Current Report on our Current Report on Form 8-K filed January 14, 2021) EXHIBIT 4.1 COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP. Warrant Shares: Initial Exercise Date: January , 2021 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Ini

LEXXW / Lexaria Bioscience Corp. - Equity Warrant - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)